Tags : Amends

Eli Lilly Amends its 2013 Agreement with Chi-Med to Commercialize

Shots: Chi-Med to receive 70%-80% of Elunate sales in the form of royalties, manufacturing costs and service payments with no upfront regarding this amendment. Lilly will maintain the exclusive commercialization rights and will continue to consolidate the sales of Elunate in China while Chi-Med retains all rights to fruquintinib outside of China The agreement allows […]Read More

Thermo Fisher Scientific Amends its Agreement to Acquire QIAGEN

Shots: Under the amended agreement, the offer price increased from $44.5 to $49/QIAGEN share in cash, representing a premium of 35% to the closing price of QIAGEN’s ordinary shares on the Frankfurt Prime Standard on Mar 2, 2020, making the latest deal value as $12.5B The amendment also provides for a reduction of the minimum […]Read More

Celgene Amends its Existing Collaboration with Editas to Develop and

Shots: Editas to receive $70M up front, milestone and royalty payments for each therapy developed by Celgene and will develop genome editing tool for which Celgene has right to opt-in to such genome editing tools for the development of gene-edited alpha-beta T cell therapies In May’2015, Editas and Juno entered into an exclusive collaboration to […]Read More

Sierra Oncology Amends its Asset Purchase Agreement with Gilead for

Shots: As per the amended agreement, Gilead will reduce the royalty rates of Momelotinib & eliminates milestone payments in exchange for becoming a stockholder in Sierra, following the closing of Sierra’s qualified financing. In Aug’2018, Sierra acquired Gilead’s Momelotinib for $3M up front, $195M milestones and royalties on sales Additionally, Sierra and Gilead Sciences would […]Read More

GSK Amends its Development and Commercialization Agreement with Liquidia for

Shots: GSK to get rights to develop and commercialize three additional inhaled therapies utilizing Liquidia’s PRINT technology and can acquire rights to pursue additional PRINT based inhalation therapies. Liquidia to receives milestones & royalties with the initiation of P-III studies In 2012, Liquidia & GSK collaborated to develop vaccines & inhaled therapies. Later in 2015, […]Read More

Pfizer and Astellas Amends Clinical Research Protocols of Xtandi for

Shots: The amendments accelerate timelines for the anticipated primary completion dates of both trials ARCHES and EMBARK Phase III trials have been amended its primary completion time from April 2020 to late 2018 and Mar-2021 to mid-2020 respectively In Oct 2009, Pfizer (Medivation) and Astellas entered into a global agreement to jointly develop and commercialize […]Read More